###### Key messages

-   This study directly compared a hemoglobin A1c and the pleiotropic effects of sitagliptin with voglibose added to concurrent treatment in Japanese patients with type 2 diabetes who could not achieve adequate glycemic control through diet therapy or a single OHA. Compared to voglibose, sitagliptin was superior to voglibose in lowering Hb1Ac levels in monotherapy and in combination therapy.

-   Sitagliptin, but not voglibose, might impair renal function. Sitagliptin significantly increased serum Cre and cys-C decreased estimated glomerular filtration rate average.

-   Sitagliptin significantly decreased polyunsaturated fatty acids, especially ω6 fatty acids, whereas voglibose altered serum levels of many kinds of fatty acids. Voglibose, but not sitagliptin, increased Δ-5 desaturase activity. Both sitagliptin and voglibose exert significant unique pleiotropic effects on surrogate cardiovascular risks.

Introduction {#s1}
============

Recent large-scale clinical trials have suggested that intensive antidiabetic therapies that cause unnecessary hyperinsulinemia do not achieve satisfactory cardiovascular outcomes in people with type 2 diabetes, as they may lead to hypoglycemia and weight gain.[@R1] To avoid these problems, incretin-based agents that do not provoke unnecessary hyperinsulinemia have been developed, and are generally used as second- or third-line therapies, in addition to metformin, in Western countries.[@R2] However, to date, limited clinical evidence is available regarding incretin-based agents as first-line or second-line antihyperglycemic therapies.

Sitagliptin is an inhibitor of dipeptidyl peptidase-4 (DPP-4), which subsequently prevents enzymatic inactivation of endogenous glucagon-like peptide-1 (GLP-1)[@R3] and thus improves glycemic control in type 2 diabetes. Sitagliptin has proven effective both as a monotherapy and in combination with other oral antihyperglycemic agents,[@R4] [@R5] although it is thought to be more effective in Asian patients than in Caucasian patients.[@R6] However, the majority of studies on sitagliptin monotherapy and combination therapy are based on non-Japanese patients, and its pleiotropic effects have not been investigated extensively, especially in Japanese patients.

Voglibose is an α-glucosidase inhibitor widely used to improve postprandial hyperglycemia. The antidiabetic actions of voglibose may be mediated, at least in part, by endogenous incretins because an α-glucosidase inhibitor may increase GLP-1 levels both by inhibiting DPP-4 activity[@R7] and by delaying intestinal absorption of a meal.[@R8] However, the differences between sitagliptin and voglibose are unknown from the perspective of understanding pleiotropic effects.

The aim of this study was to evaluate hemoglobin A1c (HbA1c) as a primary end point, and the pleiotropic effects on metabolic and cardiovascular parameters as secondary end points, of sitagliptin versus voglibose in Japanese patients with type 2 diabetes who were unable to achieve adequate glycemic control via diet therapy and/or OHA monotherapy. Notably, dynamic randomization was used to adjust for demographic differences between the groups.

Research design and methods {#s2}
===========================

Overview {#s2a}
--------

This was a randomized, parallel-group study conducted on Japanese patients. The study was designed in accordance with the principles stated in the Declaration of Helsinki, and the protocol was reviewed and approved by the appropriate institutional review board for each study site. All patients provided written informed consent before participation.

A total of 260 type 2 diabetes patients who were unable to achieve adequate glycemic control via diet therapy and/or OHA monotherapy were recruited from 19 centers in Japan between May 2011 and August 2012. Type 2 diabetes was diagnosed according to WHO criteria, based on a 2 h plasma glucose value of \>11.1 mmol/L.[@R9] Inadequate disease control was defined as having a Hb1Ac level \>6.9%. The trial was registered with the University Hospital Medical Information Network (UMIN) Clinical Trials Registry (registration number UMIN000003503).

Patient eligibility {#s2b}
-------------------

Participants were eligible if they were at least 20 years old, had type 2 diabetes mellitus, poorly controlled diabetes (HbA1c levels \>6.9% within 12 weeks before screening), and had been treated with diet therapy and/or a single OHA, such as sulfonylurea (SU), biguanide (BG) or thiazolidinedione (TZD) class drugs, for 12 weeks or longer.

Exclusion criteria were: (1) hypersensitivity or a contraindication to sitagliptin or voglibose; (2) history of type 1 diabetes; (3) history of ketoacidosis; (4) having experienced symptoms of hypoglycemia; (5) treatment with sitagliptin or voglibose within 12 weeks before screening; (6) treatment with insulin within 12 weeks before screening; (7) concomitant corticosteroid therapy; (8) poorly controlled or unstable diabetes (the state with ketoacidosis or with an increase in HbA1c \>3% in the 12 weeks before screening); (9) alanine aminotransferase and/or aspartate aminotransferase levels more than 2.5-fold the upper limit of normal; (10) poorly controlled hypertension or systolic blood pressure \>160 mm Hg or diastolic blood pressure \>100 mm Hg; (11) presence of a severe health problem not suitable for the study; (12) pregnancy or breastfeeding; or (13) inability to participate in the study due to psychiatric or psychosocial status as assessed by the investigators.

Efficacy endpoints {#s2c}
------------------

A computer-generated randomization sequence was used to assign participants in a 1:1 ratio to either the sitagliptin or voglibose treatment group. Dynamic randomization was used to adjust for demographic differences (age, previous treatment for type 2 diabetes and HbA1c level) between the groups. In this active-comparator, parallel-group trial, eligible patients received either sitagliptin or voglibose in addition to their previous treatment for 12 weeks. Sitagliptin (Merck & Co, Inc, New Jersey, USA) was initiated and maintained at 50 mg once daily. Voglibose (Takeda Pharmaceutical Company Limited, Osaka, Japan) was initiated and maintained at 0.6 mg (0.2 mg with each meal). Other medications were unchanged during the study period.

The primary efficacy end point was the change in Hb1Ac levels from baseline over the 12-week period. Secondary end points recorded at baseline and week 12 included: fasting plasma glucose (FPG); serum creatinine (Cre); uric acid; alkaline phosphatase (ALP), bone alkaline phosphatase (BAP), cystatin-C (cys-C), 1,5-anhydroglucitol (1,5-AG), fasting serum insulin (IRI), fasting serum proinsulin, fasting C-peptide immunoreactivity (CPR), factors related to fasting lipid profile (including small dense low-density lipoprotein, low-density lipoprotein-cholesterol, adiponectin, tumour necrosis factor α (TNF-α) and leptin); blood pressure; and physical measures (waist circumference, body mass index (BMI)). The estimated glomerular filtration rates based on serum Cre (eGFRcreat) and serum cys-C (eGFRcys), and the average estimated glomerular filtration rate (eGFRaverage), were calculated using the following formulas: eGFRcreat=194×Cr^−1.094^×Age^−0.287^ (males) or 194×Cr^−1.094^×Age^−0.287^×0.739 (females); eGFRcys=(104×Cystatin C^−1.019^×0.996^age^)−8 (males) or (104×Cystatin C^−1.019^×0.996^age^×0.929)−8 (females); eGFRaverage=((eGFRcreat+eGFRcys)/2).[@R10] [@R11] The homeostasis model assessment of insulin resistance (HOMA-IR) was used as a conventional index for insulin resistance and was calculated as (IRI (U/mL)×FPG (mmol/L))/22.5).[@R12] To assess basic insulin secretion by β cells, CPR index (CPI), homeostasis model assessment-β (HOMA-β), secretory unit of islet in transplantation index (SUIT index) and quantitative insulin sensitivity check index (QUICKI), were calculated as follows: CPI=(100×fasting CPR (ng/mL))/ FPG (mg/dL)),[@R13] HOMA-β=(IRI (IU/L)×20/(FPG(mg/dL)−63)),[@R14] SUIT index=(1500×CPR (ng/mL)/(FPG (mg/dL)−63))[@R15] and QUICKI=(1/(log IRI(IU/L)+log FPG (mg/dL)).[@R16]

Serum fatty acid levels were measured as a secondary outcome. A serum sample (approximately 0.2 mL) and 2 mL of a chloroform-methanol solution (2:1) were placed in a Pyrex centrifuge tube, homogenized with a Polytron homogenizer (PCU-2-110; KINEMATICA GmbH, Switzerland) and centrifuged at 3000 rpm for 10 min. An aliquot of the chloroform-methanol extract was transferred to another Pyrex tube and dried under a stream of nitrogen gas. The dried sample was dissolved in 100 µL of 0.4 M potassium methoxide methanol/14% boron trifluoride-methanol solution, and the fatty acid concentrations were measured at SRL Inc (Tokyo, Japan), using a gas chromatograph (Shimizu GC 17A, Kyoto, Japan). Desaturase activities were estimated as follows: Δ-5 desaturase, C20:4ω6/C20:3ω6; Δ-6 desaturase, 18:3ω-6/18:2ω-6.[@R17]

Medication adherence and adverse events were monitored throughout the study, and were rated by investigators for intensity and relationship to study drug.

Statistical analysis {#s2d}
--------------------

The sample size required to detect a −0.6% change in HbA1c levels in the sitagliptin group, and a −0.4% change in the voglibose group, with a power of 80% (α=0.05, one-tailed; β=0.20) and standardized effect size of 0.6, was 112 participants in each group. Taking into account a dropout rate of 15%, we aimed to recruit 260 participants. All analyses used the full analysis set, which included all patients who received at least one dose of study drug and for whom data were available at baseline and from at least one postrandomization time point. Missing data were replaced by the last observed value of each variable in this analysis. Data were expressed as the mean±SD. The Statistical Package for the Social Sciences (SPSS) V.22.0 (SPSS Inc, Chicago, Illinois, USA) was used for the statistical analyses. Parameters were analyzed using the Wilcoxon signed-rank test in the internal group comparison, the χ^2^ test or the Mann-Whitney *U*-test, or the Kruskal-Wallis test, in the intergroup comparison. Associations between variables were assessed using Spearman\'s rank correlation coefficient. Multiple regression analysis was carried out to determine independent factors for changes in HbA1c by sitagliptin or voglibose. p Values \<0.05 were considered statistically significant.

Results {#s3}
=======

Patient characteristics {#s3a}
-----------------------

A total of 260 patients were screened and randomly assigned to either the sitagliptin or voglibose regimen, and 241 participants (mean age, 63.2±12.7 years; mean BMI, 25.0±4.5 kg/m^2^) were enrolled in this study ([table 1](#BMJDRC2015000190TB1){ref-type="table"}). Nineteen patients were removed after randomisation before the intervention because they withdrew consent (n=17) or did not meet inclusion criteria (n=2; see online [supplementary figure](#SM1){ref-type="supplementary-material"} S1). No participants took EPA or docosahexaenoic acid (DHA) before or during the study and other subject medications remained unchanged during the study period. One hundred and sixteen patients received diet therapy, 61 patients received SU, 57 patients received BG and seven patients received TZD. FPG and HbA1c levels were 154.7±35.1 mg/dL and 7.9±0.9%, respectively. Baseline demographics and disease characteristics of the two groups did not differ significantly ([table 1](#BMJDRC2015000190TB1){ref-type="table"}). The serum TNF-α levels at baseline included two outliers in the sitagliptin group. The median was similar in the two groups (Sitagliptin versus Voglibose, 1.20 vs 1.10 (pg/mL)) and there was no significant difference in the Mann-Whitney U test (p=0.166).
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###### 

Characteristic of the study participants

                                           All (n=241)   Sitagliptin (n=120)   Voglibose (n=121)   p Value
  ---------------------------------------- ------------- --------------------- ------------------- ---------
  Male/Female                              143/98        72/48                 71/50               0.603
  Age (years)                              63.2±12.7     63.2±13.8             63.2±11.6           0.699
  Medication adherence rate (≥80%/\<80%)   193/48        99/21                 94/27               0.420
  Combination therapy (Diet/SU/BG/TZD)     116/61/57/7   59/29/29/3            57/32/28/4          0.953
  Body weight (kg)                         64.8±14.4     63.8±13.6             65.8±15.1           0.515
  BMI (kg/m^2^)                            25.0±4.5      25.0±4.5              25.1±4.5            0.984
  Waist circumference (cm)                 89.9±11.1     88.7±10.5             91.0±11.7           0.162
  Systolic BP (mm Hg)                      130.8±17.7    130.0±16.8            131.6±18.5          0.413
  FPG (mg/dL)                              154.7±35.1    156.3±35.1            153.2±35.2          0.347
  HbA1c (%)                                7.9±0.9       7.9±1.0               7.8±0.8             0.935
  1.5AG (μg/mL)                            6.9±4.8       6.5±4.2               7.4±5.3             0.429
  BUN (mg/dL)                              15.1±4.5      14.9±4.1              15.2±4.9            0.886
  s-Cre (mg/dL)                            0.72±0.23     0.70±0.19             0.74±0.27           0.870
  AST (IU/L)                               26±14         26±13                 26±16               0.823
  ALT (IU/L)                               31±25         32±25                 30±25               0.522
  γ-GTP (IU/L)                             46±53         44±49                 49±57               0.072
  TC (mg/dL)                               188.4±33.0    185.1±33.4            191.6.±32.4         0.130
  TG (mg/dL)                               140.1±93.6    136.0±83.1            144.2±103.1         0.899
  HDL-C (mg/dL)                            53.8±16.7     52.7±15.4             54.9±18.0           0.250
  LDL-C (mg/dL)                            106.2±28.1    105.0±29.6            107.5±26.5          0.234

Data are expressed as means±SD. p Value for the intergroup comparison.

AG, anhydroglucitol; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BG, biguanide; BMI, body mass index; BP, blood pressure; BUN, blood urea nitrogen; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; HDL-c, low-density lipoprotein cholesterol; LDL-C, low-density lipoprotein-cholesterol; s-Cre, serum creatinine; SU, sulfonylurea; TC, total cholesterol; TG, triglyceride; TZD, thiazolidinedione; γ-GTP, γ-glutamyl transpeptidase.

Clinical outcomes {#s3b}
-----------------

Compared to baseline, FPG and HbA1c levels decreased significantly in both groups at the end of the study ([table 2](#BMJDRC2015000190TB2){ref-type="table"}). Sitagliptin was superior to voglibose in lowering HbA1c levels (−0.78±0.69 vs −0.30±0.78%, respectively) and FPG concentrations (−16.2±26.4 vs −4.4±38.7 mg/dL, respectively) relative to baseline. There was no significant difference of medication adherence between the groups ([table 1](#BMJDRC2015000190TB1){ref-type="table"}). In addition, in the stratified analysis on good (≧80%) and poor (\<80%) adherence, adherence rate did not affect these results (see online [supplementary table](#SM1){ref-type="supplementary-material"} S1).

###### 

Changes in the characteristics of patients between baseline and 12 weeks

                                         Sitagliptin                        Voglibose                                      
  -------------------------------- ----- ------------- ------------ ------- ----------- ------------- ------------ ------- -------
  Body weight (kg)                 120   63.8±13.6     63.7±13.3    0.842   120         65.8±15.2     65.3±15.1    0.025   0.126
  BMI                              118   24.9±4.5      24.9±4.4     0.777   119         25.1±4.5      24.9±4.4     0.024   0.086
  Waist (cm)                       116   88.7±10.5     88.2±10.0    0.195   120         91.0±11.7     90.0±11.1    0.013   0.363
  SBP (mm Hg)                      120   130.0±16.8    129.5±17.1   0.998   121         131.6±18.5    128.9±16.7   0.067   0.265
  DBP (mm Hg)                      120   76.0±12.1     75.4±12.1    0.576   121         75.1±12.9     74.4±12.5    0.689   0.918
  WBC (/mm^3^)                     120   5815±1362     6057±1590    0.050   119         5985±1762     5940±1975    0.315   0.037
  Neutrophils (/mm^3^)             108   3279±1015     3570±1096    0.008   107         3485±1313     3431±1587    0.193   0.007
  Eosinophils (/mm^3^)             105   156±120       151±120      0.000   105         163±108       164±114      0.821   0.074
  Basophils (/mm^3^)               105   30±23         31±23        0.359   105         32±21         34±28        0.864   0.247
  Lymphocytes (/mm^3^)             105   1951±607      1866±586     0.007   105         2041±723      2023±766     0.772   0.023
  Monocytes (/mm^3^)               105   323±113       345±122      0.004   105         339±139       340±150      0.270   0.009
  PLT (10^4^/mm^3^)                120   21.0±5.5      20.8±5.6     0.281   119         21.8±6.0      21.3±5.8     0.084   0.574
  RBC (10^3^/mm^3^)                120   458.4±43.7    459.2±45.4   0.723   119         454.1±52.1    457.2±50.3   0.124   0.612
  Hb (g/mL)                        120   13.9±1.6      14.0±1.8     0.943   119         13.9±1.6      14.0±1.5     0.548   0.882
  Ht (%)                           120   41.6±4.1      41.7±4.4     0.565   119         41.3±4.2      41.8±4.0     0.030   0.399
  AST (IU/L)                       120   26±13         26±13        0.554   120         26±16         25±11        0.961   0.776
  ALT (IU/L)                       120   32±25         30±21        0.459   120         30±26         30±20        0.505   0.309
  ALP (IU/L)                       120   236±71        226±76       0.000   118         237±91        236±101      0.168   0.074
  BAP (μg /L)                      116   12.6±5.6      12.3±5.6     0.140   116         12.7±5.5      12.5±4.9     0.832   0.186
  γ-GTP (IU/L)                     120   44±50         49.2±87.6    0.836   119         49±57         47±51        0.011   0.051
  CK (IU/L)                        117   105.5±71.6    105.2±68.0   0.920   116         109.2±59.5    107.4±54.5   0.552   0.720
  BUN (mg/dL)                      120   14.9±4.1      15.0±4.6     0.838   120         15.3±4.9      14.5±4.9     0.041   0.166
  Cr (mg/dL)                       120   0.71±0.19     0.74±0.19    0.000   120         0.74±0.27     0.76±0.27    0.129   0.199
  UA (mg/dL)                       119   5.08±1.14     5.30±1.24    0.001   120         5.13±1.40     5.28±1.40    0.073   0.328
  Cystatin C (mg/L)                114   0.82±0.18     0.85±0.19    0.001   112         0.86±0.23     0.86±0.23    0.177   0.087
  eGFRcreat (mL/min/1.73 m^2^)     120   85.0±28.4     80.6±26.5    0.000   120         80.4±24.1     78.3±23.4    0.069   0.203
  eGFRcys (mL/min/1.73 m^2^)       114   91.1±23.2     91.1±29.3    0.969   112         87.9±25.0     88.5±22.9    0.626   0.132
  eGFRaverage (mL/min/1.73 m^2^)   114   88.0±23.3     85.6±24.6    0.006   111         83.7±22.2     83.4±20.8    0.687   0.053
  TC (mg/dL)                       120   185.1±33.4    184.9±39.0   0.910   118         191.6±32.4    193.6±40.8   0.066   0.272
  HDL-C (mg /dL)                   118   52.7±15.4     52.3±14.8    0.873   118         54.9±18.0     54.8±18.3    0.739   0.712
  Triglyceride (mg/dL)             120   136.0±83.1    129.8±85.5   0.098   120         144.2±103.2   129.3±79.0   0.015   0.450
  LDL-C (mg/dL)                    118   104.9±29.6    106.5±34.1   0.499   117         107.5±26.5    112.7±36.5   0.001   0.026
  sdLDL (mg/dL)                    118   36.8±15.4     34.9±15.1    0.134   120         38.0±16.6     38.3±17.6    0.831   0.220
  IRI (IU/L)                       116   8.46±8.20     8.69±9.37    0.342   118         14.1±65.1     14.2±69.5    0.028   0.039
  CPR (ng/mL)                      118   2.10±0.88     2.04±0.84    0.421   120         2.08±1.03     2.05±1.13    0.634   0.715
  HMW adiponectin (μg/dL)          118   3.17±2.30     3.50±2.57    0.000   120         3.53±3.65     3.74±3.53    0.000   0.161
  Hypersensitive TNF-α (pg/mL)     118   3.11±12.47    2.23±5.21    0.079   120         1.42±1.87     1.55±1.83    0.000   0.538
  Leptin (ng/mL)                   118   8.26±6.90     8.27±7.17    0.561   120         9.02±9.28     8.21±6.59    0.694   0.540
  HOMA-IR                          115   3.30±3.44     2.98±3.02    0.056   117         5.21±23.02    5.52±29.02   0.003   0.443
  HOMA-β                           115   36.0±32.8     47.2±57.6    0.000   117         63.7±299.6    59.5±237.4   0.408   0.002
  SUIT index                       117   39.5±30.4     45.9±28.3    0.000   118         38.0±22.1     40.9±23.8    0.004   0.047
  CPI                              117   1.41±0.67     1.52±0.71    0.001   118         1.38±0.68     1.43±0.78    0.080   0.207
  QUICKI                           112   0.34±0.04     0.34±0.04    0.093   116         0.34±0.05     0.34±0.05    0.090   0.784
  Proinsulin (pM)                  112   26.9±17.2     22.5±14.3    0.000   104         26.5±17.9     25.3±17.4    0.036   0.328
  Proinsulin/Insulin Ratio         101   0.70±0.67     0.54±0.33    0.000   91          0.63±0.39     0.65±0.49    0.698   0.015
  HbA1c (%)                        120   7.94±1.03     7.15±0.88    0.000   121         7.86±0.78     7.56±1.02    0.000   0.000
  1,5AG (μg/mL)                    109   6.45±4.16     10.55±5.96   0.000   105         7.43±5.29     12.6±8.12    0.000   0.047
  FPG (mg/dL)                      119   156.3±35.1    140.0±31.7   0.000   119         153.2±35.2    148.0±43.0   0.001   0.006

Data are expressed as means±SD.

\*p Value for the intragroup comparison (baseline vs 12 weeks).

†p Value for the intergroup comparison (difference in changes from baseline between groups).

ALT, alanine aminotransferase; ALP, alkaline phosphatase; AST, aspartate aminotransferase; BAP, bone alkaline phosphatase; BMI, body mass index; BUN, blood urea nitrogen; CK, creatinine kinase; CPI, CPR index; CPR, C-peptide immunoreactivity; Cr, creatinine; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; Hb, hemoglobin; HDL-c, low-density lipoprotein cholesterol; HMW, high molecular weight; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-β, homeostasis model assessment-β; IRI, fasting serum insulin; LDL-C, low-density lipoprotein-cholesterol; PLT, platelet; QUICKI, quantitative insulin sensitivity check index; RBC, red blood cell; SBP, systolic blood pressure; sdLDL, small dense low-density lipoprotein; SUIT, secretory unit of islet in transplantation index; TC, total cholesterol; TNF-α, tumour necrosis factor α; UA, uric acid; WBC, white blood cell count.

Both agents significantly increased 1,5-AG concentrations, but voglibose was superior to sitagliptin in this regard. Sitagliptin, but not voglibose, increased indices for insulin secretion such as HOMA-β, SUIT and CPI. Both agents lowered proinsulin levels and both agents exerted marked effects on the insulin sensitivity index, QUICKI.

Sitagliptin significantly reduced the counts of lymphocytes (p=0.007) and significantly increased the counts of neutrophils (p=0.008) at week 12, whereas voglibose had no effect on them ([table 2](#BMJDRC2015000190TB2){ref-type="table"}). Sitagliptin significantly lowered ALP levels from 236±71 IU/L at baseline to 226±76 IU/L at week 12 (p=0.000) without changing bone alkaline phosphatase (BAP), whereas voglibose had no effect on ALP levels. Both agents were almost neutral in their effects on liver enzymes, except that voglibose treatment decreased γ-GTP levels from 49±57 IU/L at baseline to 47±51 IU/L at week 12 (p=0.011). Sitagliptin, but not voglibose, increased serum Cre, uric acid and cys-C. Both agents lowered serum triglyceride levels, whereas voglibose, but not sitagliptin, significantly increased LDL-C. Voglibose significantly increased TNF-α levels, whereas sitagliptin, rather, tended to decrease TNF-α levels. Both agents significantly increased adiponectin levels. In stratified analyses on each concomitant therapy, there was no significant difference in glycemic parameters (see online [supplementary figure](#SM1){ref-type="supplementary-material"} S2). SU significantly increased neutrophils and decreased diastolic blood pressure compared to BG in the sitagliptin group (data not shown).

Factors predicting the effects of sitagliptin and voglibose are shown in [table 3](#BMJDRC2015000190TB3){ref-type="table"}. In the sitagliptin group, there was a significant correlation between ΔHbA1c and baseline levels of 1,5-AG (rs=0.338, p=0.000), HbA1c (rs=--0.589, p=0.000) and adiponectin (r=0.223, p=0.015; [table 3](#BMJDRC2015000190TB3){ref-type="table"}). There was no predicting factor in the voglibose group. In a multiple regression analysis, only baseline HbA1c was the independent factor of ΔHbA1c in the sitagiptin group (β=−0525, p=0.000, adjusted R^2^=0.268).

###### 

Factors associated with a change in HbA1c

                                   Sitagliptin   Voglibose            
  -------------------------------- ------------- ----------- -------- -------
  Baseline                                                            
  Body weight (kg)                 −0.051        0.577       −0.082   0.374
  Body mass index                  −0.142        0.126       −0.08    0.390
  Fasting plasma glucose (mg/dL)   −0.113        0.222       0.107    0.246
  1,5 AG (%)                       0.338         0.000       −0.034   0.714
  HbA1c (%)                        −0.589        0.000       −0.121   0.185
  Total cholesterol (mg/dL)        0.050         0.588       0.009    0.948
  Fasting serum insulin (IU/L)     −0.092        0.328       −0.079   0.392
  CPR (ng/mL)                      −0.101        0.275       −0.004   0.965
  HMW adiponectin (µg/mL)          0.223         0.015       0.137    0.137
  CPI                              −0.048        0.609       −0.038   0.684
  HOMAIR                           −0.128        0.171       0.114    0.222
  HOMA-β                           −0.016        0.861       0.033    0.722
  EPA (ng/mL)                      −0.064        0.490       0.062    0.502
  DHA (ng/mL)                      −0.077        0.118       −0.078   0.396
  Change from baseline                                                
   ΔFPG                            0.386         0.000       0.421    0.000
   ΔBW                             0.212         0.020       0.047    0.609
   ΔBMI                            0.206         0.025       0.058    0.533
   ΔALP                            0.269         0.003       0.187    0.042
   ΔTC                             0.231         0.011       −0.062   0.502
   ΔLDLC                           0.266         0.004       0.151    0.103
   ΔTG                             0.084         0.362       −0.152   0.098
   ΔHMW adiponectin                −0.310        0.001       −0.346   0.000
   ΔHOMA-IR                        0.233         0.012       0.105    0.262
   ΔHOMA-β                         −0.304        0.001       −0.222   0.016
   ΔSUIT index                     −0.377        0.000       −0.261   0.004
   ΔQUICKI                         −0.185        0.047       −0.175   0.060
   ΔCPI                            −0.235        0.011       −0.156   0.091
   ΔProinsulin insulin ratio       0.199         0.046       0.177    0.094
   ΔEPA                            −0.010        0.914       −0.062   0.502
   ΔDHA                            0.073         0.430       −0.065   0.482

AG, anhydroglucitol; ALP, alkaline phosphatase; BMI, body mass index; BW, body weight; CPR, C-peptide immunoreactivity; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-β, homeostasis model assessment-β; HMW, high molecular weight; LDLC, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglyceride.

Changes in fatty acid composition in serum lipids {#s3c}
-------------------------------------------------

Sitagliptin, but not voglibose, significantly decreased serum levels of total polyunsaturated fatty acids, including linoleic acid and total ω6 fatty acids. Voglibose, but not sitagliptin, significantly decreased total saturated fatty acids (including palmitic acid and stearic acid), total monounsaturated fatty acids (including palmitoleic acid and oleic acid) and some polyunsaturated fatty acids (such as γ-linolenic acid, 5,8,11-eicosatrienoic acid, dihomo-γ-linolenic acid, docosatetraenoic acid and docosapentaenoic acid). Voglibose significantly decreased the activity of Δ-6 desaturase and increased that of Δ-5 desaturase ([table 4](#BMJDRC2015000190TB4){ref-type="table"}). No correlation was observed between ΔHbA1c and eicosapentaenoic acid (EPA) levels at baseline in the sitagliptin group ([table 3](#BMJDRC2015000190TB3){ref-type="table"}).

###### 

Changes in plasma fatty acid composition between baseline and 12 weeks

                                                                    Sitagliptin                           Voglibose                                          
  --------------------------------- ----------------- ------------- -------------- -------------- ------- ------------ -------------- -------------- ------- -------
  Lauric acid                       C12:0 (ng/mL)     118           2.3±2.2        2.3±2.3        0.555   120          2.5±2.1        2.2±2.3        0.139   0.592
  Myristic acid                     C14:0 (ng/mL)     118           29.9±18.9      28.5±19.3      0.147   120          33.1±23.0      30.0±22.8      0.012   0.356
  Palmitic acid                     C16:0 (ng/mL)     118           746.7±259.6    709.8±254.1    0.019   120          796.9±268.7    747.9±265.4    0.001   0.494
  Palmitoleic acid                  C16:1ω7 (ng/mL)   118           80.3±46.2      77.0±51.6      0.130   120          89.7±51.6      82.0±53.7      0.000   0.049
  Stearic acid                      C18:0 (ng/mL)     118           214.7±53.6     212.0±28.7     0.532   120          224.2±57.7     218.2±61.8     0.033   0.291
  Oleic acid                        C18:1ω9 (ng/mL)   118           656.2±236.6    653.2±260.1    0.799   120          714.9±295.4    671.7±268.3    0.049   0.194
  Linoleic acid                     C18:2ω6 (ng/mL)   118           774.4±182.1    736.3±188.6    0.021   120          798.6±208.2    807.2±244.4    0.902   0.143
  γ-linolenic acid                  C18:3ω6 (ng/mL)   118           11.4±6.5       10.8±6.0       0.941   120          11.9±6.9       10.2±5.5       0.000   0.023
  α-Linolenic acid                  C18:3ω3 (ng/mL)   118           27.6±12.5      25.9±11.1      0.010   120          27.3±15.0      27.2±16.3      0.331   0.164
  Arachidic acid                    C20:0 (ng/mL)     118           7.2±1.3        7.3±1.6        0.876   120          7.6±1.6        7.7±1.7        0.935   0.935
  Eicosenoic acid                   C20:1ω9 (ng/mL)   118           5.5±2.0        5.3±2.2        0.562   120          6.1±6.8        6.3±6.9        0.306   0.274
  Eicosadienoic acid                C20:2ω6 (ng/mL)   118           5.9±1.8        5.9±2.0        0.599   120          6.3±2.0        6.3±21         0.764   0.929
  5-8-11Eicosatrienoic acid         C20:3ω9 (ng/mL)   118           2.2±1.4        2.2±1.6        0.549   120          2.8±2.6        2.5±2.4        0.008   0.116
  Dihomo-γ-linolenic acid           C20:3ω6 (ng/mL)   118           38.8±13.2      39.7±16.4      0.260   120          42.4±15.5      39.9±12.7      0.005   0.010
  Arachidonic acid                  C20:4ω6 (ng/mL)   118           173.2±48.7     172.0±51.3     0.706   120          184.5±46.5     183.5±44.6     0.691   0.898
  Eicosapentaenoic acid             C20:5ω3 (ng/mL)   118           80.6±48.3      79.7±43.5      0.884   120          81.2±70.0      85.5±78.4      0.659   0.955
  Behenic acid                      C22:0 (ng/mL)     118           17.9±3.3       17.9±3.6       0.838   120          32.1±3.7       19.1±4.3       0.465   0.651
  Erucic acid                       C22:1ω9 (ng/mL)   118           1.6±0.8        1.6±0.7        0.613   120          1.8±0.9        1.7±0.9        0.768   0.291
  Docosatetraenoic acid             C22:4ω6 (ng/mL)   118           5.2±2.2        5.1±2.6        0.248   120          5.5±2.3        5.1±1.9        0.011   0.306
  Docosapentaenoic acid             C22:5ω3 (ng/mL)   118           25.2±10.0      24.3±9.4       0.399   120          25.8±13.1      24.0±13.5      0.004   0.955
  Lignoceric acid                   C24:0 (ng/mL)     118           16.3±2.8       16.3±3.3       0.775   120          17.5±3.4       17.8±3.9       0.423   0.598
  Docosahexaenoic acid              C22:6ω3 (ng/mL)   118           175.2±65.3     169.5±58.7     0.305   120          175.2±94.5     167.7±96.1     0.095   0.531
  Nervonic acid                     C24:1ω9 (ng/mL)   118           34.8±7.5       34.5±7.5       0.357   120          37.0±8.2       37.7±8.0       0.028   0.028
  EPA+DHA                           (ng/mL)           118           255.9±107.5    249.2±92.6     0.536   120          256.3±160.3    253.1±169.4    0.436   0.782
  EPA/AA ratio                                        118           0.49±0.31      0.49±0.30      0.705   120          0.44±0.32      0.044±0.32     0.435   0.895
  Total ω3 fatty acids              (ng/mL)           118           308.7±121.9    299.0±105.3    0.370   120          309.4±181.0    304.3±191.6    0.308   0.735
  Total ω6 fatty acids              (ng/mL)           118           1008.7±224.8   969.8±237.7    0.024   120          1049.2±238.2   1052.3±273.9   0.684   0.239
  Total ω9 fatty acids              (ng/mL)           118           700.2±239.2    696.8±263.6    0.794   120          762.6±300.8    720.0±272.5    0.053   0.210
  ω3/ω6 ratio                                         118           0.32±0.13      0.32±0.11      0.236   120          0.30±0.14      0.30±0.14      0.409   0.151
  Total saturated fatty acids       (ng/mL)           118           1034.9±330.7   994.1±330.3    0.050   120          1101.1±346.5   1043.0±348.1   0.002   0.515
  Monounsaturated fatty acids       (ng/mL)           118           778.3±276.8    771.7±305.2    0.762   120          854.3±346.8    799.5±306.6    0.020   0.132
  Polyunsaturated fatty acids       (ng/mL)           118           1319.5±277.3   1270.9±289.2   0.014   120          1361.4±336.2   1359.0±384.4   0.562   0.233
  δ-5desaturase (20:4 ω6/20:3 ω6)   118               4.73±1.42     4.72±1.62      0.595          120     4.78±1.77    4.97±1.64      0.014          0.031   
  δ-6desaturase (18:3 ω6/18:2 ω6)   118               0.015±0.008   0.015±0.007    0.321          120     0.016±0.01   0.014±0.009    0.009          0.007   

Data are expressed as means±SD.

\*p Value for the intragroup comparison (baseline vs 12 weeks).

†p Value for the intergroup comparison (difference in changes from baseline between groups).

AA, arachidonic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid.

Adverse events {#s3d}
--------------

The incidence of AEs was significantly lower in the sitagliptin group. This difference was attributable to the decreased incidence of gastrointestinal AEs, such as heartburn, abdominal pain, constipation, loose stool, diarrhea, meteorism and flatulence. Most AEs were mild or moderate but one patient in the voglibose group discontinued the treatment due to diarrhea. The incidence of hypoglycemia was low and similar in both groups. All incidences of hypoglycemia in this study were mild or moderate in severity, but one patient in the sitagliptin group discontinued the treatment due to hypoglycemia. Four serious adverse events (SAEs)---inguinal hernia, heart failure, pancreatitis and urinary tract infection---occurred in the voglibose group, but were considered not related to the study. Due to these SAEs, three patients discontinued the agents (see online [supplementary table](#SM1){ref-type="supplementary-material"} S2).

Discussion {#s4}
==========

This study directly compared HbA1c and the pleiotropic effects of sitagliptin with voglibose added to concurrent treatment in Japanese patients with type 2 diabetes who could not achieve adequate glycemic control through diet therapy or a single OHA. The novelty of the present study is as follows: First, dynamic randomization is methodologically novel. It is useful to adjust for demographic differences between each group. In this open-label, randomized, parallel-group study with dynamic allocation, we compared sitagliptin with voglibose, not only as a monotherapy, but also as an add-on therapy to SU, BG or TZD. Second, pleiotropic effects of sitagliptin and voglibose include previously yet-recognized findings.

Regarding the primary endpoint, sitagliptin was superior to voglibose in lowering HbA1c levels in monotherapy and in combination with each concurrent agent. A similar reduction in HbA1c was also observed in previous 12-week studies.[@R18]

Regarding the secondary end points, sitagliptin and voglibose exerted unique pleiotropic effects in the present study. Sitagliptin, but not voglibose, significantly increased the markers of β-cell function (HOMA-β and proinsulin/insulin ratio). Preclinical studies have shown that GLP-1 stimulates β-cell differentiation and proliferation, inhibits apoptosis of β-cells,[@R21] [@R22] and stimulates β-cell neogenesis and survival in streptozotocin-treated rats.[@R23] In fact, several reviews have indicated that DPP-4 inhibitors consistently improve markers of β-cell function in type 2 diabetes patients.[@R20] [@R24] [@R25] A decrease in the fasting proinsulin-to-insulin ratio, consistent with improved β-cell function, was observed in association with sitagliptin treatment in a previous study.[@R26]

Sitagliptin compared with voglibose significantly reduced the counts of lymphocytes and increased those of neutrophils in the present study, as observed in the previous study.[@R27] DPP-4 is highly expressed by T-cells, especially CD4+ T-cells. Sitagliptin decreases CD4+ T-cells in a glucose-independent manner.[@R27] Whether DPP-4 inhibitors suppress immunity by reducing the number of circulating CD4+ T-cells should be examined in future. Sitagliptin significantly increased serum levels of Cre, cys-C and uric acid, and decreased eGFRcreat, whereas voglibose had no effect on these parameters in the present study. These results might relate to the Na-diuretic action of GLP-1,[@R28] although we observed no reduction in blood pressure in the present study. Therefore, it is possible that sitagliptin impairs renal function. In fact, during a much longer, 54-week study, it was found that 18.8% of patients in the sitagliptin group with moderate renal insufficiency at baseline transitioned to severe renal insufficiency status over the course of the study.[@R29] On the other hand, in our study, deterioration of eGFRcys was not observed. After 12 weeks, sitagliptin, but not voglibose, decreased ALP levels relative to baseline without affecting BAP levels. Although it is not certain whether this sitagliptin-mediated decrease in ALP is related to bone metabolism, the decrease in ALP from baseline significantly correlated with a decrease in HbA1c levels, as observed in previous studies.[@R30] [@R31]

Both sitagliptin and voglibose significantly increased plasma adiponectin levels, as stated in previous reports.[@R32] [@R33] There was a negative correlation between ΔHbA1c and Δadiponectin ([table 3](#BMJDRC2015000190TB3){ref-type="table"}), suggesting that glycemic control at least partly contributes to the increase in adiponectin levels. The increased adiponectin levels might improve endothelial function and likely yield anti-atherosclerotic effects.[@R34] In addition, baseline levels of adiponectin were negatively correlated with ΔHbA1c only in the sitagliptin group, suggesting that adiponectin level might be a predictive maker for the effect of sitagliptin in glycemic control. Serum EPA concentrations are reported to be associated with the glucose-lowering effect of DPP-IV inhibitors in Japanese patients with type 2 diabetes.[@R35] However, in our study, baseline EPA levels were not correlated with the change in HbA1c in the sitagliptin group ([table 3](#BMJDRC2015000190TB3){ref-type="table"}). On the other hand, sitagliptin significantly decreased polyunsaturated fatty acids, especially ω6 fatty acids, whereas voglibose altered serum levels of many kinds of fatty acids, unlike in a previous study with acarbose.[@R36] Notably, voglibose, but not sitagliptin, increased Δ-5 desaturase activity. Several cross-sectional studies showed that the Δ-5 desaturase activity index, which refers to the ratio of arachidonic acids to dihomo-γ-linolenic acids, is positively associated with insulin sensitivity[@R37] [@R38] and the onset of newly diagnosed type 2 diabetes,[@R39] and is negatively associated with several metabolic risk factors in patients with metabolic syndrome.[@R40] High Δ-5 desaturase activity was associated with reduced coronary heart disease risk.[@R41] Conversely, voglibose decreased Δ-6 desaturase activity. Δ-6 desaturase activity was associated with an increased probability of metabolic syndrome.[@R40] These findings suggest the possibility that voglibose, rather than sitagliptin, might reduce coronary heart disease risk by altering fatty acids profiling. However, as a limitation, because the present 3-month, open-label study was designed to compare the antihyperglycemic effects of sitagliptin and voglibose, the study duration may be insufficient to evaluate some of the pleiotropic effects. In the subgroup analysis, concomitant antidiabetic agents did not affect the results in glycemic parameters.

In summary, we showed that sitagliptin is superior to voglibose in terms of improving glycemic control as a first/second-line therapy in Japanese people with type 2 diabetes. However, both agents exert unique pleiotropic effects on surrogate cardiovascular risks, which suggests a theoretical basis for potential benefits through combined therapy. A large-scale clinical trial on cardiovascular events is required to test this hypothesis.

**Collaborators:** Clinical Centres for the ERA-DM study Chapter 1 group: Department of Disease Control and Homeostasis, Kanazawa University Graduate School of Medical Science (Kanazawa, Ishikawa), Municipal Tsuruga Hospital (Tsuruga, Fukui), Koshino Hospital (Kanazawa, Ishikawa), Ishida Hospital (Kanazawa, Ishikawa), Handa Medical Clinic (Kanazawa, Ishikawa), Yumie Takeshita, MD PhD, Toshinari Takamura, MD PhD, Toshiki Otoda, MD PhD; Ken-ichiro Kato MD, Hitomi Wakakuri, MD, Masayuki Yamada, MD, Hirofumi Misu, MD PhD, Shuichi Kaneko, MD PhD, Tsuguhito Ota, MD PhD, Takehiro Kanamori, MD, Yukiko Matsushima (coordinator), Shima Kitakata (coordinator); Public Hakui Hospital (Hakui, Ishikawa), Toshiki Otoda, MD PhD; Japanese Red Cross Kanazawa Hospital (Kanazawa, Ishikawa), Erika Hamaguchi, MD PhD, Yasuyuki Nishimura, MD PhD; Toyama City Hospital (Toyama, Toyama), Akiko Shimizu, MD PhD; Public Central Hospital of Matto Ishikawa (Matto, Ishikawa), Yuki Kita, MD PhD, Kozo Kawai, MD PhD; Kahoku Central Hospital (Kahoku, Ishikawa), Kensuke Mouri, MD; Fukui Saiseikai Hospital (Fukui, Fukui), Kosuke R Shima, MD, Yukihiro Bando, MD PhD; Kanazawa Municipal Hospital (Kanazawa, Ishikawa), Nobuhiko Koike, MD PhD.

**Contributors:** TT is the guarantor of this study and, as such, had full access to all of the data, and takes responsibility for the integrity and accuracy of the data and the analysis. YM designed the study, analysed and interpreted the data, and wrote the manuscript. YT designed the study, recruited the patients, collected clinical information, analysed and interpreted the data, and wrote the manuscript. YK, TO, KK, HT-W, HA, AS, EH, YN and TK collected clinical information. SK initiated and organized the study. All the authors have read and approved the final manuscript.

**Funding:** This work was supported by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, and Research grants from ONO Pharmaceutical Co, Ltd (to TT and SK).

**Competing interests:** None declared.

**Patient consent:** Obtained.

**Ethics approval:** Kanazawa University Hospital Institutional Review Board.

**Provenance and peer review:** Not commissioned; externally peer reviewed.

[^1]: YM, YT and TT contributed equally.
